Science Links Japan | Long-term Continuous Subcutaneous Insulin Infusion in Patients with Insulin-Dependent Diabetes Mellitus; Effectiveness for Preventing Diabetic Retinopathy and Clinical Safety.

Long-term Continuous Subcutaneous Insulin Infusion in Patients with Insulin-Dependent Diabetes Mellitus; Effectiveness for Preventing Diabetic Retinopathy and Clinical Safety.

Accession number;99A0455004

Title;Long-term Continuous Subcutaneous Insulin Infusion in Patients with Insulin-Dependent Diabetes Mellitus; Effectiveness for Preventing Diabetic Retinopathy and Clinical Safety.

Author; KAWASHIMA YASUKO (Fed. of Natl. Public Serv. and Affil. Personnel Mutual Aid Assoc., Toranomon Hosp.) KOBAYASHI TETSURO (Fed. of Natl. Public Serv. and Affil. Personnel Mutual Aid Assoc., Toranomon Hosp.) NAKANISHI KOJI (Fed. of Natl. Public Serv. and Affil. Personnel Mutual Aid Assoc., Toranomon Hosp.) HAYAKAWA AKIKO (Fed. of Natl. Public Serv. and Affil. Personnel Mutual Aid Assoc., Toranomon Hosp.) OKUBO MINORU (Fed. of Natl. Public Serv. and Affil. Personnel Mutual Aid Assoc., Toranomon Hosp.) MURASE TOSHIO (Fed. of Natl. Public Serv. and Affil. Personnel Mutual Aid Assoc., Toranomon Hosp.)

Journal Title;Journal of the Japan Diabetic Society

Journal Code:Z0279B

ISSN:0021-437X

VOL.42;NO.2;PAGE.149-156(1999)

Figure&Table&Reference;FIG.7, TBL.1, REF.19

Pub. Country;Japan

Language;Japanese

Abstract;The effectiveness of CSII in IDDM patients was evaluated in terms of preventing diabetic complications, especially diabetic retinopathy, and clinical safety. Twenty IDDM patients (age: 31.+-.10 years, mean.+-.SD; sex [M/F]: 11/9; duration of IDDM: 5.7.+-.5.1 years) were treated with CSII for 6.9.+-.5.0 (1.5-15) years. The values of HbA1c and fasting blood glucose(FBG) in these patients decreased significantly after initiation of CSII. Body weights of the IDDM patients increased and reached the maximal levels at 11 years (mean BMI 22.2kg/m2). The frequency of hypoglycemia increasted to 3-5 times higher than that in the pre-CSII period. However, life-threatening hypoglycemia did not occurr during CSII. Diabetic retinopathy developed in 2 of the patients: in one patient simple retinopathy developed 1 year after initiation of CSII and had progressed to the preproliferative stage 4 years later. Simple retinopathy in the other patient progressed to the preproliferative stage 0.3 years after CSII. Simple retinopathy disappeared in one patient 8 years after CSII. Overall frequencies of development to simple diabetic retinopathy and progression to proliferative retinopathy in the 20 patients treated with CSII was significantly lower than that in IDDM patients treated with non-CSII therapy. Long-term treatment with CSII in IDDM patients is a safe and effective insulin regimen for maintaining near-normoglycemia and preventing the development and progression of diabetic retinopathy. (author abst.)

Related Articles;